Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Strategies Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
397.5 USD -0.06% Intraday chart for Vertex Pharmaceuticals Incorporated +0.81% -2.31%
Apr. 26 Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants MT
Apr. 26 Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older CI

MarketScreener Strategies

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell diseaseVertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease December 11, 2023 at 05:47 am EST
Vertex Pharmaceuticals Incorporated : Confirms growth trajectoryVertex Pharmaceuticals Incorporated : Confirms growth trajectory May 04, 2023 at 09:35 am EDT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated
  5. MarketScreener Strategies